Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Lenalidomide Maintenance in Multiple Myeloma: A Retrospective, Nationwide, Real-World Study

Mads Harsløf, Iman Chanchiri, Trine Silkjær, Ulf Christian Frølund, Elena Manuela Teodorescu, Kristina Buchardi Nielsen, Per Ishøy Nielsen, Per Trøllund Pedersen, Katrine Fladeland Iversen, Kirsten Grønbæk, Annette J. Vangsted, Sigrun Thorsteinsdottir, Agoston Gyula Szabo

Blood (2023) 142 (Supplement 1): 1979.

https://doi.org/10.1182/blood-2023-179074

Published: 2023

Journal Articles

A Randomized Phase 2 Trial Comparing Carfilzomib-Dexamethasone Vs Observation As Maintenance after Induction with Carfilzomib-Cyclophosphamide-Dexamethasone in Salvage ASCT in Multiple Myeloma: A Trial By the Nordic Myeloma Study Group

Blood (2019) 134 (Supplement_1): 601.

https://doi.org/10.1182/blood-2019-122141

Published: 2019

Journal Articles

Clinically Suspected Cast Nephropathy: A Retrospective, Multi-Center, Real-World Study

Agoston Gyula Szabo, MD, Jonathan Thorsen, MD PhD, Charlotte Toftmann Hansen, MD PhD, Maja Ølholm Vase, MD PhD, Manuela Teodorescu, MD, Simon Bo Pedersen, MD, Simon Bertram Flæng, MD, Ulf Christian Frølund, MD, Annette Juul Vangsted, MD PhD, Torben Plesner, MD DSc

Blood (2019) 134 (Supplement_1): 5553.

https://doi.org/10.1182/blood-2019-124336

Published: 2019

Journal Articles

Validation of a New Clinical Prediction Model for Outcome in Newly Diagnosed Multiple Myeloma Patients Not Eligible for Autologous Stem-Cell Transplantation; A Population-Based Study from the Danish National Multiple Myeloma Registry

Louise Redder, MD, Tobias Wirenfeldt Klausen, M.S., Annette Juul Vangsted, MD PhD, Henrik Gregersen, MD PhD, Niels Frost Andersen, MD PhD, Robert Schou Pedersen, MD PhD, Torben Plesner, MD DSc, Mikael Frederiksen, MD, Ulf Christian Frølund, MD, Carsten Helleberg, MD, Lene Kongsgaard Nielsen, MD PhD, Morten Salomo, MD PhD, Peter Gimsing, MD DMSc, Henrik Frederiksen, MD PhD Prof, Niels Abildgaard, MD

Blood (2019) 134 (Supplement_1): 1849.

https://doi.org/10.1182/blood-2019-128074

Published: 2019

Journal Articles

A Randomized Placebo-Controlled Phase II Study of Clarithromycin or Placebo Combined with VCD Induction Therapy Prior to High-Dose Melphalan with Stem Cell Support in Patients with Newly Diagnosed Multiple Myeloma

Henrik Gregersen, MD, Niels Abildgaard, MD, Trung Hieu Do, MD, Ida Bruun Kristensen, MD, Ulf Christian Frølund, MD, Niels Frost Andersen, MD, Lene Kongsgaard Nielsen, MD, Christen Lykkegaard Andersen, MD, Tobias Wirenfeldt Klausen, M.S., Annette Juul Vangsted, MD

Blood (2017) 130 (Supplement 1): 3129.

https://doi.org/10.1182/blood.V130.Suppl_1.3129.3129

Published: 2017

Journal Articles

The Rev II Trial: Lenalidomide and Dexamethasone As Second Line Treatment in Myeloma Followed By Extended Lenalidomid Vs Len/Dex

Johan Lund, MD, Sigrid Karstorp, MD, Evren Alici, MD PhD, Astrid Gruber, MD PhD, Birgitta Lauri, MD, Cecilie Blimark, MD PhD, Agneta Swedin, MD PhD, Markus Hansson, MD PhD, Karin Forsberg, MD, Lucia Ahlberg, MD, Carlsson Conny, MD, Anders Waage, MD PhD, Peter Gimsing, Annette Juul Vangsted, MD PhD, Ulf Christian Frølund, MD, Mats Hardling, Ulf-Henrik Mellqvist, MD PhD, Hareth Nahi

Blood (2015) 126 (23): 3047.

https://doi.org/10.1182/blood.V126.23.3047.3047

Published: 2015

NARROW

Lenalidomide Maintenance in Multiple Myeloma: A Retrospective, Nationwide, Real-World Study

A Randomized Phase 2 Trial Comparing Carfilzomib-Dexamethasone Vs Observation As Maintenance after Induction with Carfilzomib-Cyclophosphamide-Dexamethasone in Salvage ASCT in Multiple Myeloma: A Trial By the Nordic Myeloma Study Group

Clinically Suspected Cast Nephropathy: A Retrospective, Multi-Center, Real-World Study

Validation of a New Clinical Prediction Model for Outcome in Newly Diagnosed Multiple Myeloma Patients Not Eligible for Autologous Stem-Cell Transplantation; A Population-Based Study from the Danish National Multiple Myeloma Registry

A Randomized Placebo-Controlled Phase II Study of Clarithromycin or Placebo Combined with VCD Induction Therapy Prior to High-Dose Melphalan with Stem Cell Support in Patients with Newly Diagnosed Multiple Myeloma

The Rev II Trial: Lenalidomide and Dexamethasone As Second Line Treatment in Myeloma Followed By Extended Lenalidomid Vs Len/Dex

Email alerts

ASH Publications

American Society of Hematology

Lenalidomide Maintenance in Multiple Myeloma: A Retrospective, Nationwide, Real-World Study

A Randomized Phase 2 Trial Comparing Carfilzomib-Dexamethasone Vs Observation As Maintenance after Induction with Carfilzomib-Cyclophosphamide-Dexamethasone in Salvage ASCT in Multiple Myeloma: A Trial By the Nordic Myeloma Study Group

Clinically Suspected Cast Nephropathy: A Retrospective, Multi-Center, Real-World Study

Validation of a New Clinical Prediction Model for Outcome in Newly Diagnosed Multiple Myeloma Patients Not Eligible for Autologous Stem-Cell Transplantation; A Population-Based Study from the Danish National Multiple Myeloma Registry

A Randomized Placebo-Controlled Phase II Study of Clarithromycin or Placebo Combined with VCD Induction Therapy Prior to High-Dose Melphalan with Stem Cell Support in Patients with Newly Diagnosed Multiple Myeloma

The Rev II Trial: Lenalidomide and Dexamethasone As Second Line Treatment in Myeloma Followed By Extended Lenalidomid Vs Len/Dex

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only